These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28226335)

  • 21. Choosing the right laboratory: a review of clinical and forensic toxicology services for urine drug testing in pain management.
    Reisfield GM; Goldberger BA; Bertholf RL
    J Opioid Manag; 2015; 11(1):37-44. PubMed ID: 25750163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urine drug testing: current recommendations and best practices.
    Owen GT; Burton AW; Schade CM; Passik S
    Pain Physician; 2012 Jul; 15(3 Suppl):ES119-33. PubMed ID: 22786451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic urine drug testing for detecting and managing opioid misuse among chronic noncancer pain patients in primary care-The HARMS Program: A retrospective chart review of 77 patients.
    Shahi N; Patchett-Marble R
    J Opioid Manag; 2020; 16(4):277-282. PubMed ID: 32885835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological and toxicological profile of opioid-treated, chronic low back pain patients entering a mindfulness intervention randomized controlled trial.
    Zgierska A; Wallace ML; Burzinski CA; Cox J; Backonja M
    J Opioid Manag; 2014; 10(5):323-35. PubMed ID: 25350474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physician Renewal of Chronically Prescribed Controlled Substances Based on Urine Drug Test Results.
    Hosain F; Lee J; Ata A; Bhullar RK; Chang AK
    J Prim Care Community Health; 2019; 10():2150132719883632. PubMed ID: 31646927
    [No Abstract]   [Full Text] [Related]  

  • 28. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observation of improved adherence with frequent urine drug testing in patients with pain.
    Yee DA; Hughes MM; Guo AY; Barakat NH; Tse SA; Ma JD; Best BM; Atayee RS
    J Opioid Manag; 2014; 10(2):111-8. PubMed ID: 24715666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provider Misinterpretation, Documentation, and Follow-Up of Definitive Urine Drug Testing Results.
    Chua I; Petrides AK; Schiff GD; Ransohoff JR; Kantartjis M; Streid J; Demetriou CA; Melanson SEF
    J Gen Intern Med; 2020 Jan; 35(1):283-290. PubMed ID: 31713040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.
    Turner JA; Saunders K; Shortreed SM; Rapp SE; Thielke S; LeResche L; Riddell KM; Von Korff M
    J Gen Intern Med; 2014 Feb; 29(2):305-11. PubMed ID: 24142119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoassay-Based Drug Tests Are Inadequately Sensitive for Medication Compliance Monitoring in Patients Treated for Chronic Pain.
    Snyder ML; Fantz CR; Melanson S
    Pain Physician; 2017 Feb; 20(2S):SE1-SE9. PubMed ID: 28226337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compliance with opioid treatment guidelines for chronic non-cancer pain (CNCP) in primary care at a Veterans Affairs Medical Center (VAMC).
    Sekhon R; Aminjavahery N; Davis CN; Roswarski MJ; Robinette C
    Pain Med; 2013 Oct; 14(10):1548-56. PubMed ID: 23746149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do Urine Drug Tests Reveal Substance Misuse Among Patients Prescribed Opioids for Chronic Pain?
    Larochelle MR; Cruz R; Kosakowski S; Gourlay DL; Alford DP; Xuan Z; Krebs EE; Yan S; Lasser KE; Samet JH; Liebschutz JM
    J Gen Intern Med; 2022 Aug; 37(10):2365-2372. PubMed ID: 34405344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of urine toxicology in chronic opioid analgesic therapy.
    Compton P
    Pain Manag Nurs; 2007 Dec; 8(4):166-72. PubMed ID: 18036504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy.
    Katz NP; Sherburne S; Beach M; Rose RJ; Vielguth J; Bradley J; Fanciullo GJ
    Anesth Analg; 2003 Oct; 97(4):1097-1102. PubMed ID: 14500164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabis Legalization Does Not Influence Patient Compliance with Opioid Therapy.
    Lo SY; Winston-McPherson GN; Starosta AJ; Sullivan MD; Baird GS; Hoofnagle AN; Greene DN
    Am J Med; 2019 Mar; 132(3):347-353. PubMed ID: 30419224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive urine drug test findings in patients prescribed opioids for pain from a large national database.
    Guevara MG; LaRue L; Zacharoff KL; Whitley P; Dawson E; Passik SD
    J Opioid Manag; 2022; 18(4):361-375. PubMed ID: 36052933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified.
    Wyse JJ; Morasco BJ; Dobscha SK; Demidenko MI; Meath THA; Lovejoy TI
    J Opioid Manag; 2018; 14(4):295-303. PubMed ID: 30234926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.